test

Genitourinary Pathology Society Lifetime Achievement Award

This award recognizes and honors GUPS members who have made significant contributions to and a broad impact on the field of urological pathology.

Nominations for the award are solicited from the GUPS membership and the Executive and Awards Committees select the recipient.

The awards are presented at the GUPS Annual General Meetings in conjunction with USCAP meetings.

This year’s recipient is Dr. Lawrence D. True, University of Washington.

Past recipients are:

1st Prize ($500)
Integrated Protein and mRNA Biomarker Assessment in a Rapid Autopsy Series of Castrate Resistant Metastatic Prostate Cancer
Dr. Rahul Mannan
Research fellow, University of Michigan
rmannan@med.umich.edu

2nd Prize ($400)
The Impact of Cribriform Pattern 4 and Intraductal Prostatic Carcinoma on NCCN and CAPRA Patient Stratification
Dr. Yan Hong (Shirley) Yu
Resident, University of Calgary
yanhong.yu@ucalgary.ca

3rd Prize ($200)
Molecular correlates of male germ cell tumor with overgrowth of component resembling “somatic” malignancies: Multi-platform analysis of a collaborative series
Dr. Nicolas Wyvekens
Resident, Brigham and Women’s Hospital
nwyvekens@bwh.harvard.edu

First Place:  Thomas Denize – Whole Slide Microvascular Density (MVD) Evaluation in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC): Association With ISUP/WHO Grade, PD-L1 Expression, and Mast Cell Infiltration.

Second Place: Jie-Fu Chen – Renal Cell Carcinoma with Fibromyomatous Stroma Associated with TSC/MTOR Alterations and ELOC (TCEB1) Mutations Differ in mTOR Activation Status Assessed by Immunohistochemistry.

Third Place:  Harsimar Kaur – Homologous Recombination Deficiency (HRD) Score in Germline BRCA2- Versus ATM-Altered Prostate Cancer.

First Place: John Kennedy – Type 1 Papillary Renal Cell Carcinomas with High Grade Features – Morphologic and Molecular Analysis.

Second Place: Ana Aula Olivar – Tumor Budding as a High Risk Prognostic Factor in Progression of pT1 Bladder Urothelial Carcinomas

Third Place: Douglas Mata – Association of KIT Mutations with Concurrent RAS/MAPK Pathway Driver Alterations in Seminomatous and Non-Seminomatous Germ-Cell Tumors